|
1
|
Dueñas-González A, García-López P, Herrera
LA, Medina-Franco JL, González-Fierro A and Candelaria M: The
prince and the pauper. A tale of anticancer targeted agents. Mol
Cancer. 7:822008.
|
|
2
|
Zaenker KS and Entschladen F: Paving roads
for new drugs in oncology. Recent Patents Anticancer Drug Discov.
4:137–145. 2009. View Article : Google Scholar
|
|
3
|
Gupta SC, Sung B, Prasad S, Webb LJ and
Aggarwal BB: Cancer drug discovery by repurposing: Teaching new
tricks to old dogs. Trends Pharmacol Sci. 34:508–517. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bernstein WB and Dennis PA: Repositioning
HIV protease inhibitors as cancer therapeutics. Curr Opin HIV AIDS.
3:666–675. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chow WA, Jiang C and Guan M: Anti-HIV
drugs for cancer therapeutics: Back to the future? Lancet Oncol.
10:61–71. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gills JJ, Lopiccolo J, Tsurutani J,
Shoemaker RH, Best CJ, Abu-Asab MS, Borojerdi J, Warfel NA, Gardner
ER, Danish M, et al: Nelfinavir, A lead HIV protease inhibitor, is
a broad-spectrum, anticancer agent that induces endoplasmic
reticulum stress, autophagy, and apoptosis in vitro and in vivo.
Clin Cancer Res. 13:5183–5194. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brüning A, Gingelmaier A, Friese K and
Mylonas I: New prospects for nelfinavir in non-HIV-related
diseases. Curr Mol Pharmacol. 3:91–97. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xiang T, Du L, Pham P, Zhu B and Jiang S:
Nelfinavir, an HIV protease inhibitor, induces apoptosis and cell
cycle arrest in human cervical cancer cells via the ROS-dependent
mitochondrial pathway. Cancer Lett. 364:79–88. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kushchayeva Y, Jensen K, Recupero A,
Costello J, Patel A, Klubo-Gwiezdzinska J, Boyle L, Burman K and
Vasko V: The HIV protease inhibitor nelfinavir down-regulates RET
signaling and induces apoptosis in medullary thyroid cancer cells.
J Clin Endocrinol Metab. 99:E734–E745. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun L, Niu L, Zhu X, Hao J, Wang P and
Wang H: Antitumour effects of a protease inhibitor, nelfinavir, in
hepatocellular carcinoma cancer cells. J Chemother. 24:161–166.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brüning A, Rahmeh M, Gingelmaier A and
Friese K: The mitochondria-independent cytotoxic effect of
nelfinavir on leukemia cells can be enhanced by sorafenib-mediated
mcl-1 downregulation and mitochondrial membrane destabilization.
Mol Cancer. 9:192010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rengan R, Mick R, Pryma D, Rosen MA, Lin
LL, Maity AM, Evans TL, Stevenson JP, Langer CJ, Kucharczuk J, et
al: A phase I trial of the HIV protease inhibitor nelfinavir with
concurrent chemoradiotherapy for unresectable stage IIIA/IIIB
non-small cell lung cancer: A report of toxicities and clinical
response. J Thorac Oncol. 7:709–715. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shim JS, Rao R, Beebe K, Neckers L, Han I,
Nahta R and Liu JO: Selective inhibition of HER2-positive breast
cancer cells by the HIV protease inhibitor nelfinavir. J Natl
Cancer Inst. 104:1576–1590. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Weiss M, Kost B, Renner-Müller I, Wolf E,
Mylonas I and Brüning A: Efavirenz causes oxidative stress,
endoplasmic reticulum stress, and autophagy in endothelial cells.
Cardiovasc Toxicol. 16:90–99. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hecht M, Erber S, Harrer T, Klinker H,
Roth T, Parsch H, Fiebig N, Fietkau R and Distel LV: Efavirenz has
the highest anti-proliferative effect of non-nucleoside reverse
transcriptase inhibitors against pancreatic cancer cells. PLoS One.
10:e01302772015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Houédé N, Pulido M, Mourey L, Joly F,
Ferrero JM, Bellera C, Priou F, Lalet C, Laroche-Clary A, Raffin
MC, et al: A phase II trial evaluating the efficacy and safety of
efavirenz in metastatic castration-resistant prostate cancer.
Oncologist. 19:1227–1228. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hecht M, Harrer T, Büttner M, Schwegler M,
Erber S, Fietkau R and Distel LV: Cytotoxic effect of efavirenz is
selective against cancer cells and associated with the cannabinoid
system. AIDS. 27:2031–2040. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Woyach JA and Johnson AJ: Targeted
therapies in CLL: Mechanisms of resistance and strategies for
management. Blood. 126:471–477. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gochhait S, Dar S, Pal R, Gupta P and
Bamezai RN: Expression of DNA damage response genes indicate
progressive breast tumors. Cancer Lett. 273:305–311. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ivashkevich A, Redon CE, Nakamura AJ,
Martin RF and Martin OA: Use of the γ-H2AX assay to monitor DNA
damage and repair in translational cancer research. Cancer Lett.
327:123–133. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Monks TJ, Xie R, Tikoo K and Lau SS:
Ros-induced histone modifications and their role in cell survival
and cell death. Drug Metab Rev. 38:755–767. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Apostolova N, Gomez-Sucerquia LJ, Moran A,
Alvarez A, Blas-Garcia A and Esplugues JV: Enhanced oxidative
stress and increased mitochondrial mass during efavirenz-induced
apoptosis in human hepatic cells. Br J Pharmacol. 160:2069–2084.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Best BM and Goicoechea M: Efavirenz -
still first-line king? Expert Opin Drug Metab Toxicol. 4:965–972.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Maggiolo F: Efavirenz: A decade of
clinical experience in the treatment of HIV. J Antimicrob
Chemother. 64:910–928. 2009. View Article : Google Scholar : PubMed/NCBI
|
